What neither has, and what no amount of rubric-building changes, is a published human trial proving it works as a fat-loss treatment
The appetite suppressant is excellent once the full effects take place
AOD-9604 has some clinical trial data, though it has not achieved widespread regulatory approval for weight loss
Unlike AHK-Cu, it is typically administered by injection rather than topically, and its mechanisms do not involve copper binding
Early adopters report benefits like increased energy, better workout endurance, and steady fat loss over months similar to the kind of recomposition one might see from starting a new workout regimen
CNS neuroscience & therapeutics, 26(1), 5-13